MPI's spinout Oncology Venture to present LiPlaCis dose-escalating PoC study …

MPI's spinout Oncology Venture to present LiPlaCis dose-escalating PoC study …

MPI's lead product, the DRP(TM) diagnostic platform, is a tool to develop tumor-derived gene signatures that may predict which cancer patients are highly likely responders to a given anticancer product. The DRP(TM) has been tested in 37 trials, where

(Visited 1 times, 1 visits today)
8
Like
Save

Comments

Comments are disabled for this post.